MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
May 17, 2021 (Issue: 1624)
The FDA has licensed MenQuadfi (Sanofi Pasteur),
a quadrivalent polysaccharide conjugate vaccine
that uses tetanus toxoid as a protein carrier, for
prevention of invasive meningococcal disease caused
by Neisseria meningitidis serogroups A, C, W,...more
- SA Mbaeyi et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.
- R Borrow et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines 2017; 16:313.
- CDC. Meningococcal Disease. Surveillance. Available at: https://bit.ly/3tL6s0J. Accessed April 29, 2021.
- In brief: New meningococcal serogroup B vaccination recommendations. Med Lett Drugs Ther 2020; 62:191.
- CI Baccarini et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naive children 2-9 Years of age: a phase III, randomized study. Pediatr Infect Dis J 2020; 39:955.
- L-J Chang et al. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine 2020; 38:3560.
- MS Dhingra et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine 2020; 38:5194.
- A Esteves-Jaramillo et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: a phase III randomized study. Vaccine 2020; 38:4405.
- G Áñez et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Hum Vaccin Immunother 2020; 16:1292.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
Article code: 1624d
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
